Psychopharmacology and Psychological Therapies

78 questions

Question 61Question →

Match each clinical vignette describing a patient with major depressive disorder to the most appropriate first-line antidepressant based on their specific comorbidities and symptom profile.

Click a left item, then click its matching right item

Items

A 34-year-old man with major depressive disorder requests treatment but is highly concerned about potential sexual dysfunction and expresses a strong desire to quit smoking.
A 78-year-old woman with major depressive disorder experiences severe difficulty initiating sleep, poor appetite, and an unintentional 5-kg (11-lb) weight loss over the past month.
A 45-year-old woman with major depressive disorder also suffers from chronic burning pain in her bilateral lower extremities due to diabetic peripheral neuropathy.
A 22-year-old woman with major depressive disorder and comorbid bulimia nervosa requires treatment, but her chart notes frequent hospitalizations for hypokalemia.

Matches

Show answer & explanation

Answer

Vignette 1 matches Bupropion; Vignette 2 matches Mirtazapine; Vignette 3 matches Duloxetine; Vignette 4 matches Fluoxetine.
Optimal pharmacotherapy for major depressive disorder relies on utilizing the unique pharmacological properties of specific antidepressants. Bupropion is ideal for patients seeking smoking cessation who wish to avoid sexual dysfunction. Mirtazapine's sedating and appetite-stimulating effects benefit patients with insomnia and weight loss. SNRIs like duloxetine treat comorbid neuropathic pain. Fluoxetine is uniquely indicated for bulimia nervosa, a condition in which bupropion is strictly contraindicated.

Step-by-Step Solution

1
Analyze the 34-year-old man's priorities (avoiding sexual side effects, quitting smoking).
Identify Bupropion as the best choice.
Bupropion acts as an NDRI, avoiding serotonergic sexual side effects, and is indicated for smoking cessation.
2
Analyze the 78-year-old woman's vegetative symptoms (insomnia, severe weight loss).
Identify Mirtazapine as the best choice.
Mirtazapine's prominent side effects include profound sedation and increased appetite, which are therapeutically highly beneficial for this specific patient.
3
Analyze the 45-year-old woman's comorbidities (major depression and diabetic neuropathy).
Identify Duloxetine as the best choice.
Duloxetine is an SNRI that has established, FDA-approved efficacy for both major depressive disorder and chronic neuropathic pain syndromes.
4
Analyze the 22-year-old woman's psychiatric comorbidity (bulimia nervosa with hypokalemia).
Identify Fluoxetine as the best choice.
Fluoxetine is FDA-approved for bulimia nervosa, whereas medications like bupropion are absolutely contraindicated due to electrolyte-induced seizure risk.

Key Concept

Antidepressant selection must be tailored to individual patients by matching the medication's specific mechanism of action and side-effect profile to the patient's unique symptoms and medical comorbidities.
Question 62Question →

A 29-year-old woman is brought to the emergency department by her partner due to worsening confusion, extreme restlessness, and tremors. Her temperature is 39.4∘C39.4^{\circ}\text{C} (102.9∘F102.9^{\circ}\text{F}), heart rate is 132/min132\text{/min}, and blood pressure is 164/98 mm Hg164/98\text{ mm Hg}. Physical examination reveals profuse diaphoresis, mydriasis, hyperreflexia, and sustained clonus in the bilateral lower extremities. Her medical history is significant for major depressive disorder treated with sertraline. Two days ago, she began taking an over-the-counter dextromethorphan syrup for a cough. Arrange the following therapeutic interventions in the most appropriate sequential order for managing this patient's condition, starting from the immediate first step to treatments reserved for progressively severe or refractory toxicity.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of interventions is: Discontinue all serotonergic medications, followed by administering intravenous fluids and lorazepam, then administering oral cyproheptadine, and finally, if necessary, initiating endotracheal intubation and non-depolarizing neuromuscular blockade.
The correct sequence follows the standard stepwise algorithm for managing serotonin syndrome. The immediate priority is discontinuing the offending serotonergic agents. If symptoms persist, supportive care with intravenous fluids and benzodiazepines (e.g., lorazepam) is initiated to control agitation, lower blood pressure, and reduce heart rate. If the patient's symptoms are moderate to severe and refractory to benzodiazepines, cyproheptadine (a 5-HT2A receptor antagonist) is administered. Finally, in critically severe cases presenting with life-threatening hyperthermia (e.g., >41.1∘C> 41.1^{\circ}\text{C}) and extreme rigidity that threatens respiratory function, endotracheal intubation and non-depolarizing neuromuscular blockade are required to prevent fatal complications.

Step-by-Step Solution

1
Diagnose the patient's condition based on the clinical presentation.
The combination of autonomic instability, altered mental status, and neuromuscular irritability (hyperreflexia, clonus) in the context of taking sertraline and dextromethorphan strongly indicates serotonin syndrome.
Accurate diagnosis is required to determine the appropriate treatment algorithm and anticipate potential complications.
2
Determine the immediate first step in management.
The immediate priority is to stop the offending agents (sertraline and dextromethorphan).
Toxicity will continue or worsen as long as the precipitating serotonergic medications are present.
3
Identify the standard first-line supportive medical treatments.
Supportive care with intravenous fluids and benzodiazepines (such as lorazepam) should be initiated to control agitation and decrease muscle hyperactivity.
Benzodiazepines help manage the hyperdynamic vitals and muscle contractions, serving as the standard initial medical therapy for mild to moderate cases.
4
Identify the next pharmacological step if supportive care fails.
Cyproheptadine should be administered if symptoms are refractory to initial supportive measures.
Cyproheptadine is a specific 5-HT2A receptor antagonist that acts as an antidote, but it is typically reserved for moderate to severe cases not responding adequately to benzodiazepines.
5
Determine the treatment of last resort for extreme, life-threatening toxicity.
Intubation and non-depolarizing neuromuscular blockade are reserved for critically severe cases.
Paralysis prevents further heat generation from extreme muscle rigidity, which is crucial for treating severe hyperthermia (e.g., temperature >41.1∘C> 41.1^{\circ}\text{C}) and preventing rhabdomyolysis.

Key Concept

The management of serotonin syndrome follows a stepwise algorithmic approach: immediate discontinuation of serotonergic agents, supportive care with benzodiazepines, administration of the serotonin antagonist cyproheptadine for refractory cases, and finally intubation/paralysis for life-threatening hyperthermia.
Question 63Question →

A patient with well-controlled depression is evaluated during a same-day appointment for acute-onset agitation, sweating, and muscle spasms. The 45-year-old male states these symptoms began roughly 12 hours ago. His medical history includes major depressive disorder, for which he takes citalopram daily. Two days ago, he strained his lower back while moving heavy boxes and received a prescription from a local urgent care facility. Vital signs show a temperature of 38.6°C (101.5°F), blood pressure of 162/94 mm Hg, and heart rate of 115/min. On physical examination, the patient appears visibly restless and diaphoretic. Neurological assessment reveals bilateral ocular clonus, generalized hyperreflexia, and sustained ankle clonus. Which of the following medications was most likely prescribed for this patient's back injury?

Show answer & explanation

Answer: Tramadol

Answer

Tramadol
Tramadol has a dual mechanism of action: it acts as a weak mu-opioid receptor agonist and also inhibits the presynaptic reuptake of serotonin and norepinephrine. When a patient already taking a selective serotonin reuptake inhibitor (SSRI) like citalopram is prescribed tramadol, the synergistic increase in intrasynaptic serotonin can precipitate serotonin syndrome. This toxidrome is classically characterized by the triad of autonomic hyperactivity (tachycardia, diaphoresis, hyperthermia), altered mental status (agitation), and distinct neuromuscular abnormalities (hyperreflexia, sustained clonus, and ocular clonus).

Step-by-Step Solution

1
Analyze the patient's acute clinical presentation.
The patient exhibits autonomic instability (fever, tachycardia, hypertension, diaphoresis), altered mental status (agitation), and neuromuscular irritability (hyperreflexia, ocular and ankle clonus).
These findings form the classic clinical triad of serotonin syndrome.
2
Review the patient's baseline medications.
The patient takes citalopram, a selective serotonin reuptake inhibitor (SSRI).
SSRIs increase baseline serotonergic tone and are the most common foundation for serotonin syndrome when combined with other serotonergic drugs.
3
Evaluate the options for a precipitating agent.
Identify which of the listed medications prescribed for back pain possesses serotonergic properties.
An interacting serotonergic medication is required to trigger this acute toxicity.
4
Select the correct medication.
Tramadol is chosen because it inhibits serotonin reuptake in addition to its primary analgesic effects.
Adding tramadol to an SSRI leads to a synergistic and dangerous increase in synaptic serotonin, precipitating the observed crisis.

Key Concept

Serotonin syndrome is a potentially life-threatening condition characterized by autonomic hyperactivity, mental status changes, and neuromuscular excitability. It is often precipitated by combining an SSRI with other serotonergic medications, such as tramadol, MAOIs, or linezolid.
Question 64Question →

Match each clinical vignette describing a patient's therapeutic intervention to the most appropriate psychological therapy modality.

Click a left item, then click its matching right item

Items

A 28-year-old patient with frequent self-harm behaviors, chronic feelings of emptiness, and a pattern of intense, unstable relationships engages in a skills-based therapy to improve distress tolerance and emotion regulation.
A 35-year-old veteran with intrusive flashbacks and hypervigilance undergoes a structured therapy that pairs recounting the traumatic narrative with guided, bilateral sensory stimulation.
A 41-year-old man with major depressive disorder participates in a short-term, goal-oriented intervention focused on identifying maladaptive automatic thoughts and scheduling pleasant activities.
A 52-year-old patient who heavily consumes alcohol expresses a desire to cut down but feels unable to do so. The provider uses a non-judgmental approach to explore this ambivalence and elicit the patient's own reasons for change.
A 24-year-old woman with severe obsessive-compulsive disorder is systematically subjected to her contamination triggers while being actively prevented from engaging in her hand-washing rituals.

Matches

Show answer & explanation

Answer

The correct pairings align each patient's clinical presentation and described therapeutic technique with its specific modality: emotion dysregulation and self-harm with Dialectical behavioral therapy; trauma narrative and bilateral stimulation with Eye movement desensitization and reprocessing; depressive cognitive distortions and behavioral activation with Cognitive behavioral therapy; substance ambivalence with Motivational interviewing; and obsession triggers with compulsion blocking with Exposure and response prevention.
Each psychological therapy utilizes specific techniques tailored to particular psychiatric disorders. Dialectical behavioral therapy is specifically tailored for borderline personality disorder, targeting self-harm and emotional lability. Eye movement desensitization and reprocessing utilizes bilateral stimulation specifically for trauma processing in PTSD. Cognitive behavioral therapy focuses on restructuring maladaptive thoughts and scheduling activities, making it first-line for depression and anxiety. Motivational interviewing is a patient-centered approach uniquely structured to resolve ambivalence in substance use and behavioral changes. Exposure and response prevention is a highly specific behavioral therapy for OCD that breaks the reinforcing cycle of obsessions and compulsions.

Step-by-Step Solution

1
Identify the underlying psychiatric condition or prominent symptoms described in each patient vignette.
Vignette 1 describes borderline personality disorder. Vignette 2 describes PTSD. Vignette 3 describes major depressive disorder. Vignette 4 describes a substance use disorder. Vignette 5 describes obsessive-compulsive disorder.
Psychological therapies are highly specific to the pathophysiology and symptom clusters of individual psychiatric disorders.
2
Identify the core therapeutic mechanism or technique being utilized in each scenario.
The techniques are distress tolerance (Vignette 1), bilateral stimulation (Vignette 2), addressing maladaptive thoughts (Vignette 3), exploring ambivalence (Vignette 4), and trigger exposure without ritual completion (Vignette 5).
Matching the technique to the theoretical framework of the therapy confirms the correct modality.
3
Correlate the diagnosis and technique to the correct evidence-based psychological therapy.
The techniques map directly to DBT, EMDR, CBT, Motivational Interviewing, and ERP, respectively.
This confirms the correct pairing for each clinical presentation.

Key Concept

Indications and core techniques of evidence-based psychological therapies.
Question 65Question →

During a routine oncology follow-up, a 52-year-old female patient reports an eight-week history of persistently low mood, loss of interest in activities she previously enjoyed, early morning awakenings, and severe fatigue. She has a history of estrogen receptor-positive breast cancer that was treated with surgical resection and radiation therapy two years ago. She is currently maintained on daily tamoxifen to prevent cancer recurrence. Vital signs include a blood pressure of 124/78 mm Hg124/78 \text{ mm Hg}, pulse of 72/min72/\text{min}, and temperature of 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}). Mental status examination reveals a tearful, blunted affect and psychomotor retardation, with no evidence of psychosis or suicidal ideation. A diagnosis of major depressive disorder is established, and pharmacotherapy is considered. Which of the following antidepressants should be strictly avoided in this patient to prevent a reduction in the efficacy of her antineoplastic therapy?

Show answer & explanation

Answer: Paroxetine

Answer

Paroxetine
Paroxetine is a strong inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme. Tamoxifen is a prodrug that relies heavily on CYP2D6 for conversion into its primary active metabolite, endoxifen, which exerts the necessary therapeutic anti-estrogen effects. Co-administration of strong CYP2D6 inhibitors (such as paroxetine or fluoxetine) with tamoxifen prevents this conversion, significantly decreasing endoxifen levels and increasing the patient's risk for breast cancer recurrence. Therefore, paroxetine must be strictly avoided in patients undergoing tamoxifen therapy.

Step-by-Step Solution

1
Identify the patient's current medication and its required metabolic pathway.
The patient is taking tamoxifen, a selective estrogen receptor modulator (SERM). Tamoxifen is a prodrug that must be converted by the hepatic enzyme CYP2D6 into its highly active metabolite, endoxifen.
Understanding the pharmacokinetics of the patient's existing therapy is necessary to anticipate potential drug-drug interactions when adding a new agent.
2
Analyze the proposed treatment for major depressive disorder in the context of CYP2D6.
The goal is to select an antidepressant that does not inhibit CYP2D6, as inhibiting this enzyme would block the activation of tamoxifen and risk breast cancer relapse.
Certain antidepressants are potent inhibitors of CYP2D6 and represent an absolute contraindication for patients on tamoxifen.
3
Evaluate the interaction profiles of the given antidepressant options.
Paroxetine (along with fluoxetine) is a strong CYP2D6 inhibitor. Venlafaxine, desvenlafaxine, escitalopram, and mirtazapine have minimal or no CYP2D6 inhibitory effects.
Identifying the strong CYP2D6 inhibitor pinpoints the medication that must be strictly avoided.

Key Concept

Pharmacokinetic interactions between tamoxifen (a CYP2D6 substrate) and specific antidepressants (potent CYP2D6 inhibitors like paroxetine and fluoxetine).
Question 66Question →

A 26-year-old man with a recent diagnosis of schizophrenia is initiated on haloperidol therapy. As his physician, you will monitor him closely for extrapyramidal symptoms (EPS). Arrange the following clinical presentations of extrapyramidal side effects in the correct chronological order based on their typical onset following the initiation of typical antipsychotic therapy, from earliest onset to latest onset.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: sustained neck contractions (acute dystonia), followed by inner restlessness (akathisia), then tremor and rigidity (parkinsonism), and finally choreoathetoid movements (tardive dyskinesia).
Extrapyramidal symptoms present in a predictable chronological sequence following the administration of dopamine D2 receptor antagonists. Acute dystonia (sustained muscle spasms) occurs earliest, within hours to days. Akathisia (inner restlessness) follows, emerging over days to weeks. Drug-induced parkinsonism (bradykinesia, rigidity, tremor) develops over weeks to months. Finally, tardive dyskinesia (involuntary choreoathetoid movements) is a late complication resulting from receptor upregulation after months to years of therapy.

Step-by-Step Solution

1
Identify the symptom that occurs most acutely (within hours to days).
Sustained, painful muscle contractions representing acute dystonia.
Acute dystonia is an immediate reaction to D2 receptor blockade in the nigrostriatal pathway.
2
Identify the symptom that emerges subacutely, typically within days to weeks.
Intense subjective inner restlessness representing akathisia.
Akathisia generally requires several days to a few weeks of antipsychotic exposure to manifest.
3
Identify the symptom that develops over weeks to months.
Resting tremor, bradykinesia, and rigidity representing drug-induced parkinsonism.
Parkinsonism takes time to develop as the dopamine-acetylcholine balance in the basal ganglia is progressively altered.
4
Identify the late-onset complication occurring after months to years.
Involuntary choreoathetoid movements representing tardive dyskinesia.
Tardive dyskinesia is caused by dopamine receptor upregulation and supersensitivity after chronic, long-term blockade.

Key Concept

The classic chronological timeline for the development of antipsychotic-induced extrapyramidal symptoms follows the sequence: Acute dystonia (hours to days), Akathisia (days to weeks), Parkinsonism (weeks to months), and Tardive dyskinesia (months to years).
Question 67Question →

Match each patient presenting with major depressive disorder to the most appropriate first-line pharmacologic treatment based on their specific comorbidities and symptom profile.

Click a left item, then click its matching right item

Items

A 62-year-old man seeking psychiatric treatment one month after an acute myocardial infarction.
A 34-year-old man exhibiting severe fatigue, hypersomnolence, and expressing a strong desire to quit smoking.
A 28-year-old woman suffering from severe insomnia, poor appetite, and unwanted weight loss over the past two months.
A 41-year-old woman who has a history of poorly controlled diabetes and complains of burning, painful peripheral neuropathy.

Matches

Show answer & explanation

Answer

Match the post-MI patient to Sertraline, the fatigued smoker to Bupropion, the patient with insomnia and weight loss to Mirtazapine, and the diabetic neuropathy patient to Duloxetine.
Each correct match utilizes the unique pharmacokinetic and pharmacodynamic properties of the antidepressants to simultaneously treat the patient's major depressive disorder and their specific comorbid symptoms, optimizing the therapeutic response while minimizing adverse effects.

Step-by-Step Solution

1
Evaluate the 62-year-old man post-MI.
Identify the need for an antidepressant with high cardiovascular safety.
Post-MI patients are vulnerable to arrhythmias and drug interactions with cardiac medications; Sertraline is the safest evidence-based choice.
2
Evaluate the 34-year-old man with fatigue and smoking history.
Select Bupropion.
Bupropion's dopaminergic and noradrenergic effects counteract fatigue, and it independently aids in smoking cessation.
3
Evaluate the 28-year-old woman with insomnia and weight loss.
Select Mirtazapine.
Mirtazapine's adverse effects of weight gain and sedation are highly therapeutic for this specific clinical presentation.
4
Evaluate the 41-year-old woman with diabetic neuropathy.
Select Duloxetine.
SNRIs like Duloxetine treat both depression and neuropathic pain effectively through modulation of descending pain pathways.

Key Concept

Tailoring antidepressant therapy based on side-effect profiles and medical comorbidities.
Question 68Question →

A 34-year-old woman is brought to the emergency department due to a sudden, severe, throbbing headache and blurred vision. Her symptoms began approximately one hour after she ingested an over-the-counter oral decongestant for a viral upper respiratory infection. Her medical history is significant for treatment-resistant atypical depression. After failing several medication trials, she was started on a new psychiatric medication four weeks ago, which has significantly improved her mood. Her temperature is 37.1°C (98.8°F), pulse is 118/min, and blood pressure is 225/125 mmHg. Physical examination reveals a diaphoretic, anxious patient in obvious distress. Neurologic examination demonstrates normal muscle tone, 2+ deep tendon reflexes globally, and absent clonus. Which of the following psychiatric medications was most likely prescribed to this patient?

Show answer & explanation

Answer: Phenelzine

Answer

The correct answer is phenelzine, a monoamine oxidase inhibitor that can cause a hypertensive crisis when combined with sympathomimetic decongestants.
The correct answer is phenelzine. Phenelzine is a monoamine oxidase inhibitor (MAOI) often utilized for treatment-resistant or atypical depression. MAOIs irreversibly inhibit the degradation of monoamines, including norepinephrine. When a patient taking an MAOI is exposed to sympathomimetic medications (such as the pseudoephedrine commonly found in over-the-counter decongestants), the excessive accumulation of norepinephrine provokes a massive systemic sympathetic response. This drug-drug interaction precipitates a severe hypertensive crisis characterized by markedly elevated blood pressure, sudden throbbing headache, diaphoresis, and blurred vision. The absence of hyperthermia and neuromuscular irritability (such as clonus or hyperreflexia) critically distinguishes this crisis from serotonin syndrome.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient is experiencing a sudden, severe hypertensive crisis (blood pressure 225/125 mmHg, severe headache) with autonomic symptoms but no neuromuscular hyperactivity.
Identifying the specific toxidrome is essential to narrow down the potential drug interactions.
2
Identify the precipitating trigger.
The symptoms began shortly after ingesting an over-the-counter oral decongestant (e.g., pseudoephedrine), which acts as a sympathomimetic agent.
Understanding the mechanism of the trigger helps deduce the underlying vulnerable state caused by the baseline medication.
3
Connect the trigger and presentation to the patient's psychiatric history.
The patient takes a medication for atypical depression. Monoamine oxidase inhibitors (MAOIs) like phenelzine are indicated for atypical depression and can cause a hypertensive crisis when interacting with sympathomimetics.
Synthesizing the interaction between the baseline medication class and the trigger confirms the diagnosis.

Key Concept

Monoamine oxidase inhibitors (MAOIs) can precipitate a life-threatening hypertensive crisis when combined with sympathomimetic agents (such as pseudoephedrine) due to excessive systemic norepinephrine accumulation.
Question 69Question →

A 31-year-old man is evaluated in the clinic due to a one-month history of overwhelming sadness, severe fatigue, and a loss of interest in his usual hobbies. During this time, he has been sleeping up to 12 hours a day and has missed multiple days of work. His wife, who accompanies him, reports that four years ago he experienced a distinct two-week period where his behavior changed dramatically. During that time, he slept only two hours a night without feeling tired, obsessively pursued a chaotic new business venture, and spoke so rapidly that others could not interrupt him. He was not hospitalized during that episode and eventually returned to his baseline. He is currently taking no medications, and his medical history is unremarkable. Which of the following is the most appropriate pharmacologic intervention for this patient's current symptoms?

Show answer & explanation

Answer: Lurasidone

Answer

Lurasidone
The patient is currently experiencing a major depressive episode, but his history of a distinct period of decreased sleep, pressured speech, and excessive goal-directed behavior confirms a prior manic episode. Therefore, his diagnosis is bipolar I disorder, currently in a depressed episode. Lurasidone is an atypical antipsychotic that is FDA-approved and widely recommended as a first-line treatment for acute bipolar depression. It provides necessary antidepressant effects without the risk of triggering a manic switch.

Step-by-Step Solution

1
Identify the patient's current clinical syndrome.
The patient has a one-month history of depressed mood, anhedonia, fatigue, and hypersomnia, fulfilling the criteria for a major depressive episode.
Establishing the current affective state is necessary to understand the immediate treatment target.
2
Evaluate the patient's psychiatric history for previous mood episodes.
The patient has a history of a two-week period characterized by decreased need for sleep, pressured speech, and goal-directed activity, which meets the criteria for a past manic episode.
A history of mania changes the diagnosis from major depressive disorder (unipolar depression) to bipolar I disorder, profoundly altering the treatment algorithm.
3
Select the appropriate pharmacotherapy for acute bipolar depression.
Lurasidone is chosen because it is an effective, first-line agent for bipolar depression.
Antidepressant monotherapy must be avoided in bipolar disorder to prevent the induction of a manic switch.

Key Concept

Patients presenting with depressive symptoms must be carefully screened for a history of mania; bipolar depression should be treated with mood stabilizers or specific atypical antipsychotics (e.g., lurasidone, quetiapine), strictly avoiding antidepressant monotherapy.
Question 70Question →

A 24-year-old medical student is diagnosed with major depressive disorder and prescribed a daily dose of escitalopram. The physician counsels the patient extensively on what to expect over the coming months regarding efficacy and adverse effects. Arrange the following clinical developments in the typical chronological order of their occurrence following the initiation of continuous selective serotonin reuptake inhibitor (SSRI) therapy.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The sequence progresses from immediate adverse side effects (hours to days), to neurovegetative improvement (1-2 weeks), to subjective mood improvement (4-6 weeks), and finally maximal therapeutic response (8-12 weeks).
Understanding the timeline of SSRI response is critical for patient counseling and safety monitoring. Upon initiation, the sudden increase in serotonin acutely stimulates receptors, causing immediate adverse effects like nausea and jitteriness within hours to days. Over the first 1 to 2 weeks, neurovegetative symptoms (sleep, energy, appetite) begin to improve. Because energy returns before mood improves, patients are at a transiently increased risk for suicide. At 4 to 6 weeks, the necessary neuroplastic changes and receptor downregulation have occurred, leading to a noticeable lift in subjective depressed mood and anhedonia. Maximal therapeutic benefit is generally achieved at 8 to 12 weeks.

Step-by-Step Solution

1
Identify the immediate effects following the first dose of an SSRI.
Early serotonergic adverse effects appear first.
Blockade of the serotonin transporter (SERT) happens immediately, leading to acute 5-HT receptor stimulation in the gut and brain, causing nausea and jitteriness before any therapeutic neuroadaptation occurs.
2
Determine the initial signs of therapeutic efficacy.
Improvement in neurovegetative symptoms occurs next.
Physical symptoms like poor energy, insomnia, and altered appetite typically respond within the first 1 to 2 weeks of continuous treatment.
3
Determine the timeframe for core emotional symptom relief.
Subjective mood and anhedonia improve later in the course of treatment.
It takes approximately 4 to 6 weeks for sustained serotonin elevation to induce the necessary downregulation of presynaptic autoreceptors and promote hippocampal neurogenesis, which is required to lift the depressed mood.
4
Identify the endpoint for evaluating a medication trial.
Maximal therapeutic response is achieved last.
Complete clinical remission or the maximum possible benefit from a specific dose usually solidifies by 8 to 12 weeks.

Key Concept

Chronological timeline of SSRI therapeutic response and adverse effects
Question 71Question →

Match each clinical presentation of a severe adverse drug reaction to the psychotropic medication most likely responsible.

Click a left item, then click its matching right item

Items

A 28-year-old woman with bipolar disorder presents with a rapidly spreading, blistering rash and mucosal ulcerations. Vitals: T 38.2°C (100.8°F), HR 105/min. Mental status: anxious but oriented. Symptoms began shortly after her medication dose was aggressively increased.
A 34-year-old man with treatment-resistant schizophrenia develops a severe sore throat and chills. Vitals: T 39.4°C (102.9°F), HR 112/min. Mental status: baseline restricted affect. Laboratory testing reveals an absolute neutrophil count of 300/mm³.
A 42-year-old man on maintenance therapy for bipolar disorder complains of urinating up to 7 liters of dilute urine daily. Vitals: BP 110/70 mm Hg, HR 88/min. Mental status: cooperative, euthymic mood. Serum sodium is 146 mEq/L.
A 22-year-old woman with bipolar disorder presents with severe epigastric pain radiating to the back and intractable nausea. Vitals: T 37.8°C (100.0°F), HR 115/min. Mental status: distressed and tearful. Serum lipase is markedly elevated.
A 45-year-old man with major depressive disorder presents with palpitations, neck stiffness, and profuse sweating shortly after eating aged meats and cheeses. Vitals: BP 215/125 mm Hg, HR 122/min. Mental status: highly anxious.

Matches

Show answer & explanation

Answer

The blistering mucosal rash matches with Lamotrigine; the fever and severe neutropenia match with Clozapine; the massive output of dilute urine matches with Lithium; the epigastric pain with elevated lipase matches with Valproate; and the hypertensive crisis matches with Phenelzine.
Each clinical vignette describes a classic, severe adverse effect uniquely associated with a specific psychotropic medication. Recognizing these distinct toxicities is crucial because they require immediate discontinuation of the offending agent and specialized supportive care.

Step-by-Step Solution

1
Evaluate the first vignette (blistering rash, mucosal ulcerations, fever after rapid medication increase).
Diagnose Stevens-Johnson syndrome, which is strongly associated with rapid titration of Lamotrigine.
Lamotrigine requires a strict, slow titration schedule to mitigate the high risk of severe dermatologic reactions.
2
Evaluate the second vignette (fever, sore throat, and dangerously low absolute neutrophil count).
Diagnose agranulocytosis, an idiosyncratic reaction strongly associated with Clozapine.
Clozapine carries a black box warning for severe neutropenia and agranulocytosis, necessitating mandatory registry and regular hematologic monitoring.
3
Evaluate the third vignette (excessive thirst, polyuria of dilute urine, mild hypernatremia).
Diagnose nephrogenic diabetes insipidus, a very common complication of Lithium.
Lithium antagonizes antidiuretic hormone (ADH) in the renal collecting tubules, impairing the kidney's ability to concentrate urine.
4
Evaluate the fourth vignette (epigastric pain radiating to the back, nausea, elevated lipase).
Diagnose acute pancreatitis, a known, potentially fatal adverse effect of Valproate.
Valproic acid has a distinct black box warning for acute pancreatitis, which can occur at any point during treatment.
5
Evaluate the fifth vignette (severe hypertension, palpitations, and diaphoresis after consuming aged foods).
Diagnose tyramine-induced hypertensive crisis.
MAOIs such as phenelzine prevent the breakdown of dietary tyramine, leading to massive catecholamine release and severe hypertension.

Key Concept

Identifying severe, life-threatening adverse effects of psychotropic medications
Question 72Question →

A 28-year-old man is brought to the emergency department with acute-onset confusion, severe diaphoresis, and shivering. He recently started taking tramadol for a back injury while on a maintenance dose of citalopram. Vital signs include temperature 39.2°C (102.6°F), blood pressure 168/98 mmHg, and heart rate 124/min. Physical examination reveals generalized hyperreflexia and inducible ankle clonus. Arrange the following steps in the correct sequential order for the evidence-based management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing serotonin syndrome is to first discontinue the offending serotonergic agents, followed by initiating supportive care, then administering intravenous benzodiazepines for initial symptom control, and finally administering cyproheptadine if symptoms remain refractory.
The algorithm for serotonin syndrome progresses logically from the least invasive and most critical causative step (stopping the offending agent) to fundamental supportive measures, followed by first-line pharmacological symptom control with benzodiazepines. Targeted antidotes like cyproheptadine are strictly reserved for moderate-to-severe cases that are refractory to standard supportive care and sedation.

Step-by-Step Solution

1
Diagnose the patient's acute toxidrome based on the clinical presentation.
The combination of an SSRI (citalopram) and an analgesic with serotonergic properties (tramadol), along with altered mental status, autonomic hyperactivity, and neuromuscular irritability (hyperreflexia and clonus), confirms the diagnosis of serotonin syndrome.
An accurate diagnosis dictates the specific toxidrome management algorithm.
2
Determine the immediate first priority in management.
Discontinuation of all serotonergic agents.
Removing the precipitating pharmacological cause is essential to halt the progression of the toxicity.
3
Determine the sequence of subsequent supportive and pharmacological interventions.
Supportive care must be established first, followed by benzodiazepines, and then cyproheptadine.
Supportive care stabilizes vital signs; benzodiazepines directly treat the agitation and hyperreflexia safely; cyproheptadine is a specific antidote utilized only when these initial measures fail to control symptoms.

Key Concept

Algorithm for the acute management of Serotonin Syndrome
Question 73Question →

A 26-year-old woman is evaluated in the emergency department for a painful rash, fever, and generalized malaise that began two days ago. She has a history of bipolar I disorder that has been stable for two years on a maintenance regimen of divalproex sodium. Six weeks ago, she experienced a major depressive episode, and her psychiatrist initiated an additional mood-stabilizing medication. The new medication was started at a standard dose of 25 mg daily for two weeks, followed by an increase to 50 mg daily. On physical examination, her temperature is 38.6°C (101.5°F). There is a widespread, erythematous, maculopapular eruption on her face, trunk, and extremities, with scattered areas of epidermal sloughing. Painful erosions are present on her buccal mucosa. Which of the following pharmacokinetic effects of the patient's maintenance medication on the newly added drug most likely precipitated this patient's current condition?

Show answer & explanation

Answer: Inhibition of hepatic glucuronidation

Answer

Inhibition of hepatic glucuronidation
The patient's presentation of fever, widespread epidermal sloughing, and mucosal erosions is highly characteristic of Stevens-Johnson syndrome (SJS). In psychiatric practice, lamotrigine is notorious for causing SJS, particularly if titrated too rapidly. This patient was on maintenance divalproex sodium (valproate) and was started on a standard lamotrigine titration schedule. Valproate is a potent inhibitor of UDP-glucuronosyltransferase (UGT), the hepatic enzyme responsible for metabolizing lamotrigine. By inhibiting glucuronidation, valproate roughly doubles the half-life and serum concentration of lamotrigine. To prevent SJS, patients taking valproate must be started on a modified, slower lamotrigine titration schedule (typically 25 mg every other day for the first two weeks). The failure to account for this pharmacokinetic inhibition resulted in rapid lamotrigine accumulation and subsequent SJS.

Step-by-Step Solution

1
Identify the patient's clinical presentation.
The patient has fever, malaise, a widespread maculopapular rash with epidermal sloughing, and mucosal erosions.
These findings are the classic presentation of Stevens-Johnson syndrome (SJS), a life-threatening mucocutaneous reaction.
2
Determine the most likely offending agent based on the psychiatric history.
The patient was recently started on a new mood stabilizer for bipolar depression. Given the risk of SJS, the new medication is almost certainly lamotrigine.
Lamotrigine is a first-line agent for bipolar depression and carries a black box warning for serious skin rashes, including SJS.
3
Analyze the drug-drug interaction occurring with the patient's maintenance medication.
The patient is on maintenance divalproex sodium (valproate). Valproate inhibits UDP-glucuronosyltransferase (UGT).
UGT is the primary enzyme responsible for the hepatic metabolism of lamotrigine.
4
Connect the pharmacokinetic interaction to the clinical outcome.
Because valproate inhibits UGT, lamotrigine clearance is reduced and its half-life is doubled. The psychiatrist used a standard titration schedule instead of the required slower schedule (e.g., 25 mg every other day), leading to toxic lamotrigine levels and precipitating SJS.
Rapid dose escalation of lamotrigine, especially in the presence of a UGT inhibitor like valproate, drastically increases the risk of SJS.

Key Concept

Valproate inhibits hepatic glucuronidation (via UGT enzymes), which doubles the half-life of lamotrigine. When co-administering these medications, the lamotrigine titration schedule must be slowed by 50% to mitigate the risk of Stevens-Johnson syndrome.
Estimated Time:1m 30s
Question 74Question →

A psychiatric hospital is updating its standardized clinical pathways for medication safety. Match each psychotropic medication with the most appropriate baseline or ongoing screening modality required to monitor its specific adverse effect profile.

Click a left item, then click its matching right item

Items

Clozapine
Lithium
Valproate
Ziprasidone

Matches

Show answer & explanation

Answer

Clozapine pairs with absolute neutrophil count; Lithium pairs with thyroid-stimulating hormone; Valproate pairs with serum transaminases; and Ziprasidone pairs with electrocardiogram.
Each psychotropic medication listed requires a distinct monitoring parameter based on its unique side effect profile: clozapine requires absolute neutrophil count for agranulocytosis, lithium requires thyroid-stimulating hormone for hypothyroidism, valproate requires serum transaminases for hepatotoxicity, and ziprasidone requires an electrocardiogram for QTc prolongation.

Step-by-Step Solution

1
Identify the primary dose-limiting or life-threatening adverse effect associated with each psychotropic medication.
Clozapine can cause agranulocytosis, lithium causes hypothyroidism, valproate causes hepatotoxicity, and ziprasidone causes QTc prolongation.
Understanding the distinct toxicity profile is necessary to select the correct screening test.
2
Correlate the identified adverse effect with the corresponding laboratory test or diagnostic study.
Agranulocytosis requires absolute neutrophil count, hypothyroidism requires thyroid-stimulating hormone, hepatotoxicity requires transaminases, and QTc prolongation requires an electrocardiogram.
Clinical guidelines mandate specific surveillance testing to prevent severe morbidity from these agents.

Key Concept

Routine safety monitoring for psychotropic medications is dictated by their distinct adverse effect profiles.
Question 75Question →

A 4444-year-old man is evaluated in the hospital for progressive agitation and confusion. He was admitted two days ago for a severe right lower extremity cellulitis caused by methicillin-resistant Staphylococcus aureus (MRSA) and was started on intravenous linezolid. He has a history of major depressive disorder and generalized anxiety disorder, for which he takes multiple stable home medications. His temperature is 39.1∘C39.1^\circ\text{C} (102.4∘F102.4^\circ\text{F}), blood pressure is 168/102168/102 mmHg, pulse is 124124/min, and respirations are 2222/min. Physical examination reveals profuse diaphoresis, bilateral mydriasis, and a resting tremor. Neurological examination is notable for pronounced hyperreflexia in the lower extremities and sustained ankle clonus. A dangerous interaction with which of the following of the patient's home medications is the most likely cause of this presentation?

Show answer & explanation

Answer: Fluoxetine

Answer

Fluoxetine
This patient's presentation of altered mental status, autonomic instability (hyperthermia, tachycardia, hypertension, diaphoresis), and prominent neuromuscular hyperactivity (hyperreflexia and clonus) is classic for serotonin syndrome. The syndrome was precipitated by the administration of linezolid. Linezolid is an antibiotic used to treat resistant Gram-positive infections (like MRSA) that also acts as a reversible, non-selective monoamine oxidase inhibitor (MAOI). When combined with a serotonergic agent like an SSRI (e.g., fluoxetine), it blocks the breakdown of serotonin, leading to massive synaptic accumulation and toxicity. Clinicians must carefully review psychiatric medication lists before initiating linezolid therapy.

Step-by-Step Solution

1
Evaluate the clinical presentation.
The patient has altered mental status, autonomic instability (fever, tachycardia, hypertension, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, sustained clonus).
Identifying the clinical triad points directly to a diagnosis of serotonin syndrome.
2
Analyze the patient's recent medication changes.
The patient was recently started on intravenous linezolid for an MRSA infection.
Linezolid is an oxazolidinone antibiotic that also possesses reversible, non-selective monoamine oxidase inhibitor (MAOI) properties.
3
Identify the contraindicated home medication.
Combining an MAOI (linezolid) with a selective serotonin reuptake inhibitor (SSRI) like fluoxetine creates a dangerous drug-drug interaction.
The concurrent use of these medications leads to impaired serotonin degradation and increased serotonin release, resulting in synaptic serotonin toxicity (serotonin syndrome).

Key Concept

Serotonin syndrome can be precipitated by combining a selective serotonin reuptake inhibitor (SSRI) with linezolid, an antibiotic that possesses monoamine oxidase inhibitor (MAOI) activity.
Question 76Question →

A consultation-liaison psychiatry team is reviewing common adverse effects of various psychotropic medications to update hospital safety protocols. Match each clinical presentation of an adverse drug reaction with the medication most likely responsible.

Click a left item, then click its matching right item

Items

Polyuria, polydipsia, new-onset fine tremor, and elevated thyroid-stimulating hormone (TSH).
Excessive sialorrhea, generalized tonic-clonic seizures, and severe neutropenia.
Rapidly spreading maculopapular exanthem with oral mucosal blistering and epidermal detachment.
Acute altered mental status, asterixis, and hyperammonemia in the setting of elevated transaminases.

Matches

Show answer & explanation

Answer

The presentations match as follows: polyuria/tremor/hypothyroidism with Lithium; sialorrhea/seizures/neutropenia with Clozapine; mucosal blistering rash with Lamotrigine; and hyperammonemic encephalopathy with Valproate.
Each psychotropic medication has a distinct adverse effect profile that is critical for clinical monitoring. Lithium causes nephrogenic diabetes insipidus and hypothyroidism. Clozapine causes agranulocytosis and lowers the seizure threshold. Lamotrigine can cause Stevens-Johnson syndrome. Valproate can cause hyperammonemic encephalopathy and hepatotoxicity.

Step-by-Step Solution

1
Analyze the first clinical presentation (polyuria, tremor, elevated TSH).
Identified as lithium-induced adverse effects.
Lithium affects renal concentrating ability (nephrogenic DI) and thyroid gland function, and commonly causes a fine tremor.
2
Analyze the second presentation (sialorrhea, seizures, neutropenia).
Identified as clozapine toxicity.
Clozapine is unique among antipsychotics for causing agranulocytosis, hypersalivation, and a significantly increased risk of seizures.
3
Analyze the third presentation (mucosal blistering, epidermal detachment).
Identified as Stevens-Johnson syndrome/Toxic epidermal necrolysis caused by lamotrigine.
Lamotrigine is strongly associated with life-threatening rashes, particularly if titrated too rapidly.
4
Analyze the fourth presentation (hyperammonemia, hepatotoxicity, asterixis).
Identified as valproate-induced hyperammonemic encephalopathy.
Valproate interferes with the urea cycle, leading to hyperammonemia and subsequent encephalopathy presenting with asterixis.

Key Concept

Adverse effect profiles of psychotropic medications
Question 77Question →

A 2121-year-old woman is evaluated in the primary care clinic for a three-month history of persistent sadness, hypersomnolence, and low energy. She also mentions a strong desire to quit smoking cigarettes but has been unsuccessful with nicotine replacement therapy. Her temperature is 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure is 105/70 mmHg105/70\text{ mmHg}, and pulse is 84/min84/\text{min}. Her body mass index is 18.4 kg/m218.4\text{ kg/m}^2. Physical examination is notable for bilateral parotid gland hypertrophy, enamel erosion on her lingual tooth surfaces, and hyperkeratotic calluses on the dorsum of her right hand. Laboratory results show a serum potassium of 3.2 mEq/L3.2\text{ mEq/L}. The physician is considering a pharmacologic intervention that can address both her mood disorder and tobacco dependence. Which of the following medications is most strongly contraindicated in this patient?

Show answer & explanation

Answer: Bupropion

Answer

Bupropion
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) frequently utilized for treating major depressive disorder and for smoking cessation. However, a major adverse effect of bupropion is that it lowers the seizure threshold in a dose-dependent manner. Because of this risk, bupropion is absolutely contraindicated in patients with seizure disorders and those with a history of anorexia nervosa or bulimia nervosa. This patient's presentation features hypokalemia, parotid gland hypertrophy, dental enamel erosion, and calluses on the dorsum of the hand (Russell sign), which are all classic signs of bulimia nervosa with self-induced vomiting. The electrolyte abnormalities (e.g., hypokalemia, hyponatremia) inherent to purging behaviors structurally increase the risk of seizures, making the administration of bupropion exceptionally dangerous.

Step-by-Step Solution

1
Analyze the patient's physical examination and laboratory findings to identify any underlying, undiagnosed conditions.
The patient has parotid gland hypertrophy, dental enamel erosion, calluses on the dorsum of the right hand (Russell sign), and hypokalemia. These findings are classic for bulimia nervosa with recurrent self-induced vomiting.
Identifying the comorbid condition is crucial because eating disorders strongly dictate which psychopharmacologic agents are safe to use.
2
Determine the clinical indications for the medications being considered.
The physician is seeking a medication that treats both depression and tobacco dependence, which strongly suggests bupropion as the intended agent.
Understanding the primary indication helps evaluate the appropriateness of the chosen therapy.
3
Evaluate the safety and contraindications of bupropion in the context of the patient's bulimia nervosa.
Bupropion is an absolute contraindication in patients with eating disorders due to an unacceptably high risk of triggering seizures, especially in the presence of electrolyte derangements like hypokalemia.
Medication safety must be prioritized over dual-indication benefits when absolute contraindications exist.

Key Concept

Bupropion is absolutely contraindicated in patients with eating disorders (such as anorexia nervosa or bulimia nervosa) because it lowers the seizure threshold, and these patients are already at increased risk for seizures due to electrolyte imbalances.
Estimated Time:1m 15s
Question 78Question →

A 28-year-old woman comes to the psychiatry clinic complaining of a 4-week history of severely depressed mood, hypersomnolence, hyperphagia, and feeling that her "limbs are weighed down by lead." She has been unable to attend her job as an accountant for the past two weeks. Her medical history is notable for a psychiatric hospitalization three years ago when she was brought to the emergency department by police after staying awake for six consecutive days, spending her entire life savings on lottery tickets, and telling bystanders she was a "prophet of wealth." She was stabilized on a medication at that time but discontinued it one year ago because she disliked the required routine blood tests. She currently takes no medications and uses no illicit substances. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

Show answer & explanation

Answer: Initiate quetiapine

Answer

Initiate quetiapine
This patient has a history of a manic episode characterized by grandiosity, decreased need for sleep, and impulsivity requiring hospitalization, which definitively establishes a diagnosis of bipolar I disorder. She was likely previously treated with lithium, given her aversion to routine blood tests. She is currently presenting with a major depressive episode. The treatment of bipolar depression differs significantly from unipolar major depressive disorder. First-line monotherapy options for bipolar depression include quetiapine, lurasidone, cariprazine, and lamotrigine (though lamotrigine requires slow titration and is not ideal for acute, severe symptoms). The correct answer recommends initiating quetiapine, which is an atypical antipsychotic with robust evidence for efficacy in acute bipolar depression.

Step-by-Step Solution

1
Analyze the patient's psychiatric history to establish a correct diagnosis.
The patient has a history of a severe manic episode (decreased need for sleep, grandiosity, impulsive spending requiring hospitalization) three years ago.
A single manic episode confirms the diagnosis of bipolar I disorder, regardless of current symptoms.
2
Evaluate the patient's current clinical presentation.
The patient is currently experiencing a major depressive episode with atypical features (hypersomnolence, hyperphagia, leaden paralysis).
Identifying the current phase of bipolar disorder dictates the appropriate pharmacological intervention.
3
Select the appropriate evidence-based pharmacotherapy for the current phase.
Quetiapine is selected as the optimal treatment.
First-line monotherapy options for bipolar depression include quetiapine, lurasidone, cariprazine, or the olanzapine-fluoxetine combination. Antidepressant monotherapy must be avoided.

Key Concept

Patients with bipolar I disorder presenting with a major depressive episode should be treated with mood stabilizers or atypical antipsychotics approved for bipolar depression (e.g., quetiapine, lurasidone) rather than antidepressant monotherapy to avoid precipitating a manic switch.
PreviousPage 4 / 4